Bildkälla: Stockfoto

Cellavision: Q4’22, Challenges continues. - Redeye

Redeye’s first view on the Q4 report this morning. Cellavision clearly continues to see challenges evident in the weaker-than-expected report this morning. The organic growth was negative 17% in the quarter, whereas the Americas and APAC were particularly weak this quarter. The challenges seen in Q3 seem to linger longer than expected.

Redeye’s first view on the Q4 report this morning. Cellavision clearly continues to see challenges evident in the weaker-than-expected report this morning. The organic growth was negative 17% in the quarter, whereas the Americas and APAC were particularly weak this quarter. The challenges seen in Q3 seem to linger longer than expected.
Börsvärldens nyhetsbrev
ANNONSER